NBIX - Neurocrine Biosciences, Inc.
| Previous Close | 84.32 |
| Open | 84.32 |
| Bid | 84.63 x 1100 |
| Ask | 84.61 x 1000 |
| Day's Range | 83.95 - 85.05 |
| 52 Week Range | 64.72 - 126.98 |
| Volume | 57,953 |
| Avg. Volume | 1,218,301 |
| Market Cap | 7.674B |
| Beta (3Y Monthly) | 2.05 |
| PE Ratio (TTM) | 384.09 |
| EPS (TTM) | 0.22 |
| Earnings Date | Apr 29, 2019 - May 3, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 1995-12-29 |
| 1y Target Est | 106.50 |
- Zacks•7 days ago
CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?
CTLT vs. NBIX: Which Stock Is the Better Value Option?
- Markit•11 days ago
See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIXView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for NBIX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding NBIX totaled $1.85 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- GuruFocus.com•11 days ago
Neurocrine Biosciences Inc (NBIX) Files 10-K for the Fiscal Year Ended on December 31, 2018
Neurocrine Biosciences Inc engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. Warning! GuruFocus has detected 2 Warning Signs with NBIX. For the last quarter Neurocrine Biosciences Inc reported a revenue of $131.5 million, compared with the revenue of $94.52 million during the same period a year ago.
- Thomson Reuters StreetEvents•13 days ago
Edited Transcript of NBIX earnings conference call or presentation 5-Feb-19 9:30pm GMT
Q4 2018 Neurocrine Biosciences Inc Earnings Call
- Benzinga•13 days ago
The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 5) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Array ...
Motley Fool•14 days agoNeurocrine Biosciences Inc (NBIX) Q4 2018 Earnings Conference Call Transcript
NBIX earnings call for the period ending December 31, 2018.
- Zacks•14 days ago
Neurocrine Biosciences (NBIX) Beats Q4 Earnings Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of 35.71% and -0.84%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•14 days ago
Neurocrine: 4Q Earnings Snapshot
The San Diego-based company said it had profit of 19 cents per share. The results beat Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for earnings ...
- PR Newswire•14 days ago
Neurocrine Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results
INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $130.3 Million with Approximately 22,900 TRx INGREZZA® (valbenazine) Full-Year 2018 Net Product Sales of $409.6 Million with Approximately 71,500 ...
- ACCESSWIRE•14 days ago
Neurocrine Biosciences, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 5, 2019 / Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 6, 2019 ...
- Benzinga•14 days ago
The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 4) AEterna Zentaris Inc. (NASDAQ: AEZS ) Axsome Therapeutics ...
- American City Business Journals•19 days ago
Here are Boston-area biotechs pursuing Parkinson's treatments
The continued need for new Parkinson's disease treatments drew attention this week, with one local gene therapy biotech striking a $165 million collaboration deal, while another companies' drug was rejected by the FDA.
- Motley Fool•21 days ago
Here's Why Voyager Therapeutics Stock Soared as Much as 62.9% Today
The company just licensed four drug programs for a cool $165 million up-front payment -- with the potential to receive $1.7 billion in future milestone payments.
- Market Realist•21 days ago
Why Is Voyager Therapeutics Soaring Today?
Why Is Voyager Therapeutics Soaring Today?Share price movements Today, Voyager Therapeutics (VYGR) issued a press release announcing a strategic collaboration with Neurocrine Biosciences (NBIX). The partnership focuses on the development and
- Zacks•21 days ago
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•21 days ago
Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinson’s Disease and Friedreich’s Ataxia
Collaboration leverages strengths and efforts of both companies towards developing and commercializing life-changing treatments for severe neurological diseases Neurocrine.
- Zacks•22 days ago
Will Neurocrine Biosciences Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Neurocrine Biosciences, Inc.
- GlobeNewswire•25 days ago
Analysis: Positioning to Benefit within Neurocrine Biosciences, CONMED, TripAdvisor, Ryder System, Nordstrom, and Express — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Jan. 25, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- PR Newswire•last month
New INGREZZA® (valbenazine) Analysis Published in the Journal of Affective Disorders Demonstrates Sustained Improvement in Tardive Dyskinesia Symptoms in Patients with Primary Mood Disorders
SAN DIEGO, Jan. 16, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that a new analysis of INGREZZA® (valbenazine) capsules, published in the Journal of Affective Disorders1, demonstrated sustained improvement in tardive dyskinesia (TD) symptoms in patients with primary mood disorders. In the post-hoc analysis, INGREZZA significantly reduced involuntary movements associated with TD in patients with a primary mood disorder, such as bipolar and major depressive disorder, and was generally well tolerated with no clinically meaningful changes to psychiatric stability. INGREZZA is the first U.S. Food and Drug Administration (FDA) approved treatment for adults with TD, a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts.
- Zacks•last month
4 Defensive Stocks to Buy Amid Shutdown and Brexit
Defensive equities could ride out market unpredictability.
- MarketWatch•last month
Here’s your guide to the upcoming biotechnology takeover wave
Biotechnology companies have been hit so hard, Big Pharma is now picking them off one by one in takeovers. This makes biotech companies look very attractive. In the weakness, for example, Celgene (CELG) hit its lowest price-to-earnings ratio in history, or around six.
- PR Newswire•last month
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2018 Financial Results
SAN DIEGO, Jan. 15, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that it will report fourth quarter and year-end 2018 financial results after the Nasdaq market closes on Tuesday, Feb. 5, 2019. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a Company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Participants can access the live conference call by dialing 877-876-9174 (US) or 785-424-1669 (International) using the conference ID: NBIX.
- ACCESSWIRE•last month
Today's Research Reports on Trending Tickers: Moderna and Neurocrine Biosciences
NEW YORK, NY / ACCESSWIRE / January 14, 2019 / U.S. equities posted strong weekly gains, however, stock closed lower for the day on Friday on concerns over an ongoing U.S. government shutdown and worries ...
